Balyasny Asset Management
DNTH icon

Balyasny Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Balyasny Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8M Buy
+474,085
New +$27.5M 0.05% 419
2025
Q4 		– Sell
-443,703
Closed -$17.5M – 3191
2025
Q3 		$17.5M Buy
+443,703
New +$11.3M 0.02% 776
2024
Q2 		– Sell
-13,371
Closed -$401K – 2683
2024
Q1 		$401K Buy
+13,371
New +$291K ﹤0.01% 2140
2022
Q4 		– Sell
-761
Closed -$17K – 2875
2022
Q3 		$17K Buy
+761
New +$20.8K ﹤0.01% 2596

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's DNTH Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 474,085 shares worth $39.8M. The stake represents 0.05% of the portfolio and ranks #419 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in DNTH as recently as Q3 2025.

Balyasny Asset Management first reported a position in DNTH in Q3 2022 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Balyasny Asset Management held 474,085 shares of Dianthus Therapeutics worth $39.8M as of Q1 2026.
  • Dianthus Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Dianthus Therapeutics made up 0.05% of Balyasny Asset Management's portfolio in Q1 2026, its #419 holding.
  • Balyasny Asset Management first reported a position in Dianthus Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.